We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

11 hedge funds and large institutions have $9.35M invested in BioXcel Therapeutics in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.33% less ownership

Funds ownership: 1.3% → 0.97% (-0.33%)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

42% less funds holding

Funds holding: 19 → 11 (-8)

63% less capital invested

Capital invested by funds: $25M → $9.35M (-$15.6M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 8

Holders
11
Holders Change
-8
Holders Change %
-42.11%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
5
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$46.5K
2
Deutsche Bank
Deutsche Bank
Germany
+$10.8K
3
TRCT
Tower Research Capital (TRC)
New York
+$4.22K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$84

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.41M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$1.25M
3
AIM
Artemis Investment Management
United Kingdom
-$484K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$146K
5
Squarepoint
Squarepoint
New York
-$142K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
1
Artemis Investment Management
United Kingdom
$4.5M -$484K -5,740 -7%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$3.32M -$2.41M -28,575 -35%
California Public Employees Retirement System
3
California Public Employees Retirement System
California
$1.15M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$224K -$1.25M -14,874 -80%
BlackRock
5
BlackRock
New York
$59K -$1.43K -17 -2%
UBS Group
6
UBS Group
Switzerland
$49K +$46.5K +551 +226%
Deutsche Bank
7
Deutsche Bank
Germany
$19K +$10.8K +128 +66%
Morgan Stanley
8
Morgan Stanley
New York
$16K -$5.65K -67 -21%
Bank of Montreal
9
Bank of Montreal
Ontario, Canada
$5K +$84 +1 +1%
TRCT
10
Tower Research Capital (TRC)
New York
$4K +$4.22K +50 +250%
Wells Fargo
11
Wells Fargo
California
$1K – – –
Point72 Asset Management
12
Point72 Asset Management
Connecticut
– -$146K -1,191 Closed
Squarepoint
13
Squarepoint
New York
– -$142K -1,156 Closed
Creative Planning
14
Creative Planning
Kansas
– -$102K -834 Closed
CMBA
15
C.M. Bidwell & Associates
Hawaii
– -$19K -156 Closed
CSS
16
Cubist Systematic Strategies
Connecticut
– -$6K -46 Closed
PHK
17
Point72 Hong Kong
Hong Kong
– -$3K -28 Closed
Bank of America
18
Bank of America
North Carolina
– -$1K -12 Closed

BTAI Hedge Fund Activity: Q4 2018 in Review

11 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q4 2018, worth a combined $9.35M — down 63% from $25M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of BTAI and 0 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 4 added.

The largest buyer was UBS Group, adding an estimated $46.5K. The largest seller was Fidelity Investments, cutting an estimated $2.41M.

  • 11 institutional investors held BioXcel Therapeutics (BTAI) as of Q4 2018, down from 19 in Q3 2018.
  • Funds reported $9.35M of BioXcel Therapeutics stock for Q4 2018, down 63% quarter-over-quarter.
  • 0 funds opened new BioXcel Therapeutics positions in Q4 2018 and 8 closed out, a net change of -8 holders.
  • The largest BioXcel Therapeutics buyer in Q4 2018 was UBS Group, an estimated $46.5K added.
  • The largest BioXcel Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $2.41M sold.

Based on aggregated 13F filings for Q4 2018.